Melanoma cells treated with GGTI and IFN-γ allow murine vaccination and enhance cytotoxic response against human melanoma cells

PLoS ONE

Volumn 5, Issue 2, 2010, Pages

  Sarrabayrouse, Guillaume ^a,b,c   Pich, Christine ^a,b,c   Moriez, Raphaël ^d   Armand Labit, Virginie ^a,b,c   Rochaix, Philippe ^b   Favre, Gilles ^a,b,c   Tilkin Mariamé, Anne Françoise ^a,b  

^a University of Toulouse III   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d CEMAGREF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GGTI 298; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; BENZAMIDE DERIVATIVE; CD86 ANTIGEN; CYTOKINE; HLA ANTIGEN CLASS 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CANCER TRANSPLANTATION; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOKINE PRODUCTION; CYTOTOXICITY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; LUNG METASTASIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA B16; MELANOMA CELL; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN MODIFICATION; TREATMENT RESPONSE; TUMOR GROWTH; VACCINATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CYTOLOGY; DRUG EFFECT; EXPERIMENTAL MELANOMA; IMMUNOLOGY; LEUKEMIA CELL LINE; MELANOMA; METABOLISM; METHODOLOGY; MONONUCLEAR CELL; PATHOLOGY; T LYMPHOCYTE; TUMOR CELL LINE; UPREGULATION;

MURINAE;

ANIMALS; ANTIGENS, CD86; BENZAMIDES; BLOTTING, WESTERN; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERFERON-GAMMA; JURKAT CELLS; LEUKOCYTES, MONONUCLEAR; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES; UP-REGULATION; VACCINATION;

EID: 77949360950     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009043     Document Type: Article

References (27)

1. Tilkin-Mariame AF, Cormary C, Ferro N, Sarrabayrouse G, Lajoie-Mazenc I, et al. (2005) Geranylgeranyl transferase inhibition stimulates anti-melanoma immune response through MHC Class I and costimulatory molecule expression. FASEB J 19: 1513-1515.
2. Luo W, Ko E, Hsu JC, Wang X, Ferrone S (2006) Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects. J Immunol 176: 6046-6054.
3. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP (2006) Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6: 383-393.
4. Akiyama Y, Maruyama K, Nara N, Mochizuki T, Yamamoto A, et al. (2004) Cytotoxic T cell induction against human malignant melanoma cells using HLAA24-restricted melanoma peptide cocktail. Anticancer Res 24: 571-577.
5. Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, et al. (2001) A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A 98: 10290-10295.
6. Godelaine D, Carrasco J, Lucas S, Karanikas V, Schuler-Thurner B, et al. (2003) Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol 171: 4893-4897.
7. Shu S, Cochran AJ, Huang RR, Morton DL, Maecker HT (2006) Immune responses in the draining lymph nodes against cancer: implications for immunotherapy. Cancer Metastasis Rev 25: 233-242.
8. Cormary C, Hiver E, Mariame B, Favre G, Tilkin-Mariame AF (2005) Coexpression of CD40L and CD70 by semiallogenic tumor cells induces antitumor immunity. Cancer Gene Ther 12: 963-972.
9. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998.
10. Cormary C, Gonzalez R, Faye JC, Favre G, Tilkin-Mariame AF (2004) Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules. Cancer Gene Ther 11: 497-507.
11. Sojka DK, Donepudi M, Bluestone JA, Mokyr MB (2000) Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. J Immunol 164: 6230-6236.
12. Coral S, Sigalotti L, Altomonte M, Engelsberg A, Colizzi F, et al. (2002) 5-aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res 8: 2690-2695.
13. Hori Y, Kikuchi A, Isomura M, Katayama M, Miura Y, et al. (1991) Post-translational modifications of the C-terminal region of the rho protein are important for its interaction with membranes and the stimulatory and inhibitory GDP/GTP exchange proteins. Oncogene 6: 515-522.
14. Bredel M, Pollack IF, Freund JM, Hamilton AD, Sebti SM (1998) Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth. Neurosurgery 43: 124-131; discussion; 131-122.
15. Allal C, Pradines A, Hamilton AD, Sebti SM, Favre G (2002) Farnesylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298. Cell Cycle 1: 430-437.
16. Kusama T, Mukai M, Tatsuta M, Matsumoto Y, Nakamura H, et al. (2003) Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor. Clin Exp Metastasis 20: 561-567.
17. Lu J, Chan L, Fiji HD, Dahl R, Kwon O, et al. (2009) In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. Mol Cancer Ther 8: 1218-1226.
18. Reinke S, Koniger P, Herberth G, Audring H, Wang H, et al. (2005) Differential expression of MART-1, tyrosinase, and SM5-1 in primary and metastatic melanoma. Am J Dermatopathol 27: 401-406.
19. Benlalam H, Vignard V, Khammari A, Bonnin A, Godet Y, et al. (2007) Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients. Cancer Immunol Immunother 56: 515-526.
20. Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C (2001) Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res 61: 1095-1099.
21. Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, et al. (2006) Blockade of PDL1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 119: 317-327.
22. Yokoyama WM, Maxfield SR, Shevach EM (1989) Very early (VEA) and very late (VLA) activation antigens have distinct functions in T lymphocyte activation. Immunol Rev 109: 153-176.
23. Botella-Estrada R, Escudero M, O'Connor JE, Nagore E, Fenollosa B, et al. (2005) Cytokine production by peripheral lymphocytes in melanoma. Eur Cytokine Netw 16: 47-55.
24. Aktas E, Kucuksezer UC, Bilgic S, Erten G, Deniz G (2009) Relationship between CD107a expression and cytotoxic activity. Cell Immunol 254: 149-154.
25. Hersey P, Si Z, Smith MJ, Thomas WD (1994) Expression of the co-stimulatory molecule B7 on melanoma cells. Int J Cancer 58: 527-532.
26. Sarrabayrouse G, Synaeve C, Leveque K, Favre G, Tilkin-Mariame AF (2007) Statins stimulate in vitro membrane FasL expression and lymphocyte apoptosis through RhoA/ROCK pathway in murine melanoma cells. Neoplasia 9: 1078-1090.
27. Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Lienard D, et al. (1999) High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 190: 705-715.